|
PEARL-II
|
GT1b treatment-experienced (N = 179)
|
3-DAA + RBV, 12 weeks (n = 88)
|
97%(85/88)
|
| | |
3-DAA only, 12 weeks (n = 91)
|
100% (91/91)
|
|
PEARL-III
|
GT1b treatment-naive (N = 419)
|
3-DAA + RBV, 12 weeks (n = 210)
|
99% (209/210)
|
| | |
3-DAA only, 12 weeks (n = 209)
|
99% (207/209)
|
|
PEARL-IV
|
GT1a treatment-naive (N = 305)
|
3-DAA + RBV, 12 weeks (n = 100)
|
97% (97/100)
|
| | |
3-DAA only, 12 weeks (n = 205)
|
90% (185/205)
|
|
TURQUOISE-II
|
GT1 treatment-naive and treatment-experienced with compensated cirrhosis (N = 380)
|
3-DAA + RBV, 12 weeks (n = 208)
|
92% (191/208)
|
| | |
3-DAA + RBV, 24 weeks (n = 172)
|
96% (165/172)
|
|
SAPPHIRE-I
|
GT1 treatment-naive (N = 631)
|
3-DAA + RBV, 12 weeks (n = 473)
|
96% (455/473)
|
|
SAPPHIRE-II
|
GT1 treatment-experienced (N = 394)
|
3-DAA + RBV, 12 weeks (n = 297)
|
96% (286/297)
|
